Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer

Wound Repair and Regeneration

Volumn 8, Issue 6, 2000, Pages 480-493

  Margolis, David J ^a   Crombleholme, Timothy ^a   Herlyn, Meenhard ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

H5 020CMV; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC FOOT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; VIRUS RECOMBINANT; WOUND HEALING;

ANIMALS; CLINICAL TRIALS, PHASE I; DIABETIC FOOT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FOLLOW-UP STUDIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-SIS; RABBITS; SENSITIVITY AND SPECIFICITY; SKIN; WOUND HEALING;

EID: 0034479597     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.2000.00480.x     Document Type: Article

References (66)

1. Management of diabetic mid-foot ulcers
2. Diabetes in America, 2. NIH Publication no. 95-1468
3. Comparing the incidence of lower extremity amputations across the world: The global lower extremity amputation study
4. Incidence, outcomes, and cost of foot ulcers in patients with diabetes
5. The epidemiology of diabetic foot problems
6. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration
7. Epidemiology of lower-extremity amputations in the indian health service. 1982-87
8. Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers
9. The description and classification of diabetic foot lesions
10. Diabetic foot disease - Where is the evidence?
11. Chronic cutaneous ulcers. Etiology and epidemiology
12. Quality of life in chronic leg ulcer patients. An assessment according to the Nottingham Health Profile
13. The epidemiology of diabetic neuropathy
14. Long-term prognosis after healed amputation in patients with diabetes
15. Quality of life issues in patients with diabetes and lower extremity ulcers: Patients and care givers
16. Wound healing in diabetes. Outcome and costs
17. Cost of diabetes-related amputations in minorities
18. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers
19. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers
20. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
21. Randomized prospective double-blinded trial in healing chronic foot ulcers
22. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings
23. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers
24. Risk factors for amputation in patients with diabetes mellitus: A case control study
25. The epidemiology of diabetic foot problems
26. Epidemiology of lower-extremity amputations in the indian health service, 1982-87
27. Medical risk factors in diabetic patients with foot ulcers and severe peripheral vascular disease and their influence on outcome
28. Consensus development conference on diabetic wound care
29. Safety of vein bypass grafting to the dorsal pedal artery in diabetic patients with foot infections
30. Peroneal artery bypass: A multifactorial analysis
31. Diabetic versus nondiabetic limb-threatening ischemia: Outcome of percutaneous iliac intervention
32. Amputation and prevention by vascular surgery and podiatry collaboration in high-risk diabetic and nondiabetic patients
33. Foundations of good ulcer care
34. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers
35. Amputation prevention in a high-risk population through comprehensive wound-healing protocol
36. Aetiology of the diabetic foot ulceration: A role for the microcirculation?
37. Diabetic Foot Ulcers: Etiology, treatment, and prevention
38. A prospective study of risk factors for diabetic foot ulcer
39. Predictors of transcutaneous oxygen tension in the lower limbs of diabetic subjects
40. Diabetic neuropathy
41. Guidelines for the diagnosis and outpatient management of diabetic periperal neuropathy
42. Defining loss of protective sensation in the diabetic foot
43. Healing of diabetic neuropathic foot ulcers receiving standard treatment: A meta analysis
44. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent
45. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers
46. Electrical nerve stimulation improves healing of diabetic ulcers
47. The total contact cast for the management of neuropathic plantar ulceration of the foot
48. Management of chronic venous leg ulcers: A literature-guided approach
49. A systematic review of compression treatment for venous leg ulcers
50. Drug treatment of chronic venous insufficiency and venous ulceration: A review
51. Wound repair: Overview and general considerations
52. Wound healing - Aiming for perfect skin regeneration
53. Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor
54. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women
55. Pharmacologic enhancement of wound healing
56. Detection of platelet-derived growth factor (PDGF) -AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds
57. Reduced expression of PDGF and PDGF receptors during impaired wound healing
58. The basic science of gene therapy
59. Packaging capacity and stability of human adenovirus type 5 vectors
60. Gene therapy: Adenovirus vectors
61. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer
62. Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing
63. Adenoviral-mediated gene transfer in wound healing: Acute inflammatory response in human skin in the SCID mouse model
64. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing
65. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
66. Management of cancer pain